1 reports of this reaction
4.2% of all Trelegy reports
#6 most reported adverse reaction
ASTHMA is the #6 most commonly reported adverse reaction for Trelegy, manufactured by Aurobindo Pharma Limited. There are 1 FDA adverse event reports linking Trelegy to ASTHMA. This represents approximately 4.2% of all 24 adverse event reports for this drug.
Patients taking Trelegy who experience asthma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASTHMA is moderately reported among Trelegy users, representing a notable but not dominant share of adverse events.
In addition to asthma, the following adverse reactions have been reported for Trelegy:
The following drugs have also been linked to asthma in FDA adverse event reports:
ASTHMA has been reported as an adverse event in 1 FDA reports for Trelegy. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASTHMA accounts for approximately 4.2% of all adverse event reports for Trelegy, making it a notable side effect.
If you experience asthma while taking Trelegy, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.